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Connected with the intestinal tract through the portal circulation, liver sinusoids function as the first line of defense
against extrahepatic stimuli such as bacterial products and other toxic substances. Hepatic stellate cells (HSCs) are
pericytes residing in the perisinusoidal space, between sinusoidal endothelial cells and hepatocytes, store vitamin A,
and regulate sinusoidal circulation. Following chronic hepatitis, HSCs actively produce extracellular matrices and
cause liver fibrosis. In spite of their close position to the liver sinusoids, however, whether HSCs contribute to liver
inflammation has remained elusive. Evidence now accumulates to suggest that HSCs actively take part in the
regulation of various forms of liver inflammation. Upon inflammatory stimuli from the sinusoids, HSCs produce
various inflammatory molecules and interact with other liver cells, thereby recruiting and then activating infiltrating
leukocytes and ultimately causing hepatocyte death. On the other hand, HSCs also exert hepatoprotective effects
through inhibition of cytokine and chemokine production or induction of immunosuppressive cell population. HSCs
therefore integrate cytokine-mediated inflammatory responses in the sinusoids and relay them to the liver
parenchyma, either amplifying liver inflammation or suppressing parenchymal damage through immunoregulatory
signaling depending on the context.
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The liver is not only an organ of metabolism and detoxi-
fication but also the site where active immune responses
take place. It is supplied by both systemic and portal
circulation; 20 % of the blood comes from the hepatic
artery and 80 % from the portal vein [1]. Various toxic
substances, such as bacterial components and food an-
tigens, are absorbed from the gut and first carried into
the liver via the portal vein. Indeed, the concentrations
of bacterial endotoxin in the systemic circulation were
significantly lower than those of the portal vein [2],
showing the potent filtering capacity of the liver.
Liver sinusoids, connected directly to the portal circu-
lation, serve as the first barrier against these noxious
stimuli. They contain various cell types, including sinus-
oidal endothelial cells, Kupffer cells (liver macrophages),
and hepatic stellate cells (HSCs). Kupffer cells and sinus-
oidal endothelial cells, facing the sinusoidal lumen and* Correspondence: ftom@ak.med.kyoto-u.ac.jp
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first line of defense against immune and inflammatory
challenges [1, 3], producing inflammatory chemokines
and cytokines and thereby attracting inflammatory cells
from the systemic circulation and lymphoid organs.
HSCs reside in the space of Disse, the abluminal side
of the sinusoids between liver sinusoidal endothelium
and hepatocytes. They represent 5–8 % of all liver cells
and 13 % of sinusoidal cells [4]. Physiological roles of
HSCs include storage of vitamin A, synthesis of extracel-
lular matrices (ECM) and matrix-degrading metallopro-
teinases, and regulation of sinusoidal blood flow. HSCs
are regarded as pericyte equivalents in the liver. Like
pericytes in other organs, HSCs are responsible for the
regulation of blood flow and the production of ECM in
inflammatory states. Upon liver injury, HSCs are acti-
vated, lose lipid-rich granules and transdifferentiate into
α-smooth muscle actin (α-SMA)-positive myofibroblasts,
which produce increased amount of ECM, and proin-
flammatory as well as profibrogenic cytokines, and cause
liver fibrosis.le is distributed under the terms of the Creative Commons Attribution 4.0
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well-recognized and attracts much attention [5], their
role in liver inflammation has been little documented.
Considering their anatomical position, HSCs appear to
respond to inflammatory signaling from the sinusoids.
HSCs from both human [6] and rodents [6, 7] produce
cytokines and chemokines upon aberrant stimuli such as
lipopolysaccharide (LPS) and other toxic substances,
suggesting that HSCs can potentially regulate hepatic
immune and inflammatory responses through their own
gene expression. However, whether HSCs take part in the
development of liver inflammation, and if so, whether they
take on pro- or anti-inflammatory roles, is still controver-
sial. We will review the recent findings on the roles of
HSCs in acute and chronic liver inflammation.
HSCs in immune-induced hepatitis
Concanavalin A (ConA) and LPS first activate immune
cells in the sinusoids upon entry into the circulation and
induce liver injury through massive production of in-
flammatory cytokines and chemokines by intra- and ex-
trahepatic immune cells, followed by intraparenchymal
infiltration of inflammatory cells [8]. Here, we discuss
the roles of HSCs in these immune-mediated liver in-
flammation models.
ConA-induced hepatitis
ConA is a lectin, a member of the family of carbohydrate-
binding proteins. Intravenously injected ConA constitu-
tively activates intrahepatic and systemic immune cells
[9, 10]. Upon entry into the sinusoids, ConA binds to
glycoproteins on the surface of Kupffer cells and sinusoidal
endothelial cells. Sinusoidal endothelial cell barrier is dis-
rupted by ConA [11, 12], which allows access of cytokines
and sinusoidal cells to HSCs and hepatocytes. Inflammatory
cytokines thus produced along with cells thus recruited in
the liver cause massive liver injury. Among the numerous
cytokines and chemokines produced in the liver, tumor
necrosis factor (TNF)-α and interferon-γ (IFN-γ) are of
high importance. Genetic deletion of TNF receptors
[13] or IFN-γ [14] or neutralizing anti-TNF (TNF-α,
lymphotoxin-α, and lymphotoxin-β) [15] or anti-IFN-γ
antibody [16] attenuates ConA hepatitis in mice. In
contrast to the above described roles of Kupffer cells
and sinusoidal endothelial cells, contribution of HSCs
to ConA hepatitis has not been investigated.
Our recent work [6] shows that HSCs receive inflam-
matory signals generated in the sinusoids and relay them
to the liver parenchyma. In this work to clarify the role
of prostaglandin D2 (PGD2) in liver pathophysiology, we
found that mice deficient in PGD receptor DP1 showed
exacerbated hepatitis after ConA injection, whereas
administration of a DP1-specific agonist BW245C sig-
nificantly suppressed liver inflammation induced byConA. Bone marrow chimera studies suggested that
DP1 expressed in non-hematopoietic cells is the target
of BW245C. Consistently, DP1 is expressed exclusively
in HSCs in the liver, while PGD synthase is induced in
Kupffer cells after ConA injection, suggesting that
PGD2 produced by Kupffer cells acts locally on HSCs
to exert the protective effects. BW245C significantly
suppressed intrahepatic and serum concentrations of
TNF-α and IFN-γ, and DNA microarray analysis of the
liver cDNA showed DP1 stimulation in HSC-inhibited
expression of numerous TNF-α- and/or IFN-γ-inducible
proinflammatory genes, which include Nos2 (inducible
nitric oxide synthase (iNOS)), Tf (tissue factor), Edn1
(endothelin-1), Vcam1 (vascular cell adhesion molecule-1
(VCAM-1)), and Sele (E-selectin). Decreased expression of
these genes may have ameliorated hepatocyte damage,
sinusoidal leukocyte accumulation, and hemostasis in
ConA- and BW245C-treated mice.
In addition, our study also indicates that HSCs control
CD4+ T cell trafficking to liver parenchyma. While CD4+
T cells were scattered in the parenchyma of the liver of
ConA-treated mice, the cells failed to enter the liver par-
enchyma and formed clusters in periportal connective
tissues in BW245C-administered, ConA-treated mice.
Similar to skin pericytes which navigate neutrophils to
the site of inflammation through intercellular adhesion
molecule-1 (ICAM-1) [17], HSCs may serve as the hub
for the intraparenchymal migration of CD4+ T cells.
Since VCAM-1 is essential in CD4+ T cell adhesion on
hepatic sinusoidal walls [18, 19], DP1-mediated suppres-
sion of lymphocyte migration from the periportal space
to the liver parenchyma could in part be due to the de-
creased VCAM-1 expression by BW245C.
These findings suggest the role of HSCs in ConA-
induced hepatitis as follows. Upon ConA injection, massive
production of inflammatory cytokines such as TNF-α and
IFN-γ occurs in the sinusoids first by Kupffer cells and T
cells and secondarily by HSCs in a paracrine manner. This
amplification of cytokine production leads to a series of
deleterious events (see Fig. 1), all of which contribute to
massive liver injury. At the same time, PGD2 is produced
by Kupffer cells, acts on DP1 of HSCs, and suppresses in-
flammatory responses to limit the amplification loop of
liver inflammation. PGD2-DP1 system in the liver may thus
serve as the brake on constitutive hepatic inflammation that
would otherwise take place due to continuous external in-
flammatory stimuli carried into the liver via enterohepatic
circulation.
LPS/GalN-induced hepatitis
Intraperitoneal injection of LPS binds to TLR4 expressed
in immune cells in the circulation and the sinusoids and
activates them, which causes massive hemorrhagic liver


















Fig. 1 Schematic diagram of the proinflammatory effects of HSCs in liver inflammation. Inflammatory signals, such as bacterial products or toxic
substances entering the liver through the portal circulation, first encounter immune cells and endothelial cells in the sinusoids. Immune cells
(Kupffer cells and leukocytes) produce large amount of inflammatory cytokines and chemokines, which in turn damage endothelial cells and act
on HSCs. Sinusoidal inflammation amplifies in a paracrine manner, causing hepatocyte injury through cytokines themselves or through infiltration
of leukocytes into the liver parenchyma
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simultaneously with a hepatotoxic agent D-galactosamine
(GalN) to inhibit the protein synthesis and to promote cell
death in hepatocytes, and this model of hepatitis is termed
LPS and D-galactosamine (LPS/GalN) liver injury [20].
We found the suppression of LPS/GalN liver injury by
DP1 stimulation and concomitant decrease in systemic
and intrahepatic TNF-α levels [6]. Others observed at-
tenuated liver injury after LPS administration in HSC-
depleted mice, with decreased cytokine and chemokine
expression [21]. These data, along with those of ConA-
induced hepatitis, suggest that HSCs are involved in
the pathogenesis of liver injury initiated by sinusoidal
inflammation.
HSCs in I/R liver injury
Ischemia and reperfusion (I/R) injury is a major complica-
tion of liver transplantation. It is induced by temporary
liver ischemia of dissected liver graft and restoration
of hepatic blood flow after transplantation. In liver
transplantation, it is one of the major problems that
affect the clinical outcomes [22]. During the ischemic
period, hepatocytes are primarily affected by ischemia
through mitochondrial damage and imbalances in pH
and electrolytes. Endothelial cell damage, disturbance
of microcirculation through up-regulation of a vaso-
constrictive peptide endothelin-1 and its receptor
endothelin-A receptor, and Kupffer cell activation also
ensue. These lead to liver inflammation and injury
through massive increase in reactive oxygen species
and inflammatory mediators [22]. Reperfusion injury
mainly involves reactive oxygen species generation byendothelial cells and neutrophils triggered by the reentry
of oxygen into the liver tissue. During I/R liver injury,
HSCs contribute to microcirculatory disturbances by
acquiring a contractile phenotype through activation by
inflammatory mediators [22].
Although HSCs have direct access to immune cells in
the sinusoids due to endothelial cell damage, their role
in the regulation of sinusoidal inflammation has not
been studied in detail. However, several recent reports
point to the proinflammatory properties of HSCs in I/R
liver injury. A model for depleting HSCs was developed
to elucidate the role of HSCs in I/R liver injury [21].
Transgenic mice expressing the herpes simplex virus
thymidine kinase gene driven by the mouse GFAP pro-
motor were treated with carbon tetrachloride to induce
HSC proliferation and render them susceptible to cell
killing induced by subsequent ganciclovir treatment.
This method resulted in depletion of 64–72 % of HSCs.
Liver injury caused by I/R, along with TNF-α, CXCL1,
and endothelin-A receptor expression, was attenuated in
HSC-depleted mice compared with controls. Histological
studies further revealed decreased neutrophil infiltration
and parenchymal cell death. These findings suggest that
HSCs are, at least in part, involved in hepatic production
of CXCL1 and contribute to neutrophil recruitment and
microcirculatory failure caused by endothelin-A receptor
stimulation.
Another group activated or depleted HSCs through
pharmacological activation of endocannabinoid recep-
tors CB1 or CB2, respectively [23], and examined their
roles in I/R liver injury. CB1 stimulation activates HSCs
and enhances liver fibrosis whereas that of CB2 causes
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α-SMA. They first found that, after reperfusion, more
than 25 % of CD4+ T cells adhering to the sinusoidal
walls colocalized with HSCs in vehicle-treated mice.
Activation of HSCs with a CB1 agonist increased non-
perfused liver areas with no significant changes in CD4+ T
cell recruitment, whereas their depletion with a CB2 agon-
ist resulted in the attenuation of CD4+ T cell infiltration
and reduced sinusoidal perfusion failure and liver enzyme
activities. These data show that CD4+ T cells interact with
HSCs before entering the hepatic parenchyma and suggest
the possibility that HSCs may serve as sentinels in T cell
migration into the parenchyma [23]. Hepatoprotective
property of HSCs is also observed [25]. Adoptive transfer
of HSCs induced the expansion of regulatory T cells (Treg
cells) in the liver and provided partial protection
against I/R liver injury, and depletion of Treg cells
abolished the protective effect of HSCs, suggesting the
cross talk between HSCs and Treg cells in hepatopro-
tection [25]. Further studies are required to define the
precise roles of HSCs in I/R liver injury and delineate
the spatiotemporal regulation of their actions.
HSCs in NASH
Nonalcoholic steatohepatitis (NASH) is distinguished from
nonalcoholic fatty liver in that NASH is characterized by
the presence of intrahepatic inflammation accompanied by
hepatocyte damage with or without fibrosis [26]. Upon liver
injury, various liver resident cells such as Kupffer cells and
HSCs are activated and, at the same time, inflammatory
cells are recruited into the liver. This results in the amplifi-
cation of intrahepatic inflammation and hepatocyte damage
progresses further, leading to tissue fibrosis in some cases.
Increased intestinal permeability is recently highlighted as a
primary cause of liver injury in NASH [27]. Gut microbiota
easily flow into the liver through the portal circulation, thus
activating Toll-like receptors (TLRs) in liver cells, TLR4 in
particular [28]. There have been numerous reports on the
important roles of TLR4, which binds LPS. Serum LPS
levels are elevated in patients with NASH and in animal
models of NASH [29, 30], suggesting the activation of
TLR4. TLR4 activation in HSCs induces the production of
chemokines and the expression of adhesion molecules
ICAM-1 and VCAM-1 [31, 32]. Furthermore, TLR4 sig-
naling in HSCs promotes the interaction between HSCs
and Kupffer cells by promoting the chemotaxis of
Kupffer cells and up-regulating the expression of adhe-
sion molecules in HSCs [32]. Down-regulation of trans-
forming growth factor (TGF)-β pseudoreceptor BAMBI
also occurs in HSCs by TLR4 ligation and activates TGF-β
signaling, resulting in increased ECM production by HSCs
and resulting fibrosis [32]. These findings provide evidence
that HSCs are actively involved in the intrahepatic inflam-
mation in NASH.HSCs in viral hepatitis
Hepatitis B and C virus (HBV and HCV, respectively) are
main causes of chronic hepatitis and cirrhosis. In some
patients, hepatocellular carcinoma (HCC) ensues, which
in many cases is difficult to treat [33]. Hepatitis viruses
replicate primarily in hepatocytes, causing mitochondrial
injury and reactive oxygen species (ROS) formation [34].
Then, viral peptides presented with HLA elicit acquired
immune responses by T cells [35]. Resident macrophages
(Kupffer cells) and other immune cells recruited into the
liver produce ROS and inflammatory as well as fibrogenic
mediators. This results in the activation of HSCs accom-
panied by increased collagen synthesis [34].
Accumulating evidence suggests that HSCs play a role
in HCV-induced chronic hepatitis [36]. The cross talk
between HCV-infected hepatocytes and HSCs is demon-
strated in an in vitro study [37]. Coculture of HSCs and
HCV-infected hepatocytes induced CCL3 production by
HCV-infected hepatocytes, which was mediated by HSC-
derived IL-1α. IL-1α induces acute-phase response in the
liver [38], and its expression is augmented in the liver of
HCV-infected patients [39]. HCV proteins themselves can
also elicit inflammatory and fibrogenic responses by HSCs
[40]. HCV core protein induces cell proliferation and
nonstructural proteins augment ICAM-1 expression
and chemokine production through the NF-κB and c-Jun
N-terminal kinase pathways in activated HSCs [40].
Finally, in the liver of chronic hepatitis C patients, CCR7
on HSCs induced cell migration and activation of several
inflammatory pathways in response to CCL21 secreted by
activated dendritic cells, resulting in induction of proin-
flammatory genes in HSCs [41].
HSCs in HCC
HCC develops from several underlying diseases, such as
viral hepatitis, alcoholic liver diseases, and NASH. The
vast majority of HCC cases are preceded by liver fibrosis,
with 90 % of hepatoma arising from cirrhotic livers [42].
Activated HSCs residing in the fibrous tissue, along with
immune cells, contribute to the formation of tumor
microenvironment favorable for tumor growth [43]. Tumor
microenvironment is a mixture of tumor cells, stromal
cells, and inflammatory molecules and ECM produced
from the stromal cells, mainly HSCs in the case of HCC.
Activated HSCs in the tumor stroma continuously produce
ECM. Dysregulation of tissue inhibitor of metalloprotein-
ases 1 (TIMP-1), which favors matrix deposition, and
matrix metalloproteinases (MMPs), which degrade ECM,
leads to increased collagen I deposition in the stroma and
contributes to HCC progression [42, 44, 45]. HSCs in active
state also produce soluble factors favoring tumor growth,
such as hepatocyte growth factor and TGF-β [42], and
proangiogenic factors such as vascular endothelial
growth factor-A (VEGF-A) and MMP9 [46]. Malignant
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and chemokines that promote the survival of activated
HSCs. HCC-HSC cross talk is vital in forming a tumor
microenvironment that contributes to HCC survival
and progression. In another concept, HSCs favor the
survival and expansion of immunosuppressive cell pop-
ulations. HSCs cause imbalance of T cell population by
accelerating activated T cell apoptosis and expanding
Treg cells [47–49]. Consistent with the above findings,
HSCs cotransplanted with HCC cells support the implant-
ation and growth of implanted tumor cells [47, 50].
HCC emerges from non-cirrhotic liver as well, notably
in nonalcoholic fatty liver diseases including NASH [51].
Here, carcinogenesis has been linked to the secretion of
inflammatory cytokines from adipose tissue, lipid accu-
mulation in hepatocytes, and resulting hyperinsulinemia
[51]. Unlike HCC resulting from chronic viral hepatitis,
hepatoma cells in non-cirrhotic HCC are well-differentiated
and tumors grow in a large nodular pattern [52]. It has
been argued that HSCs may play only a minor role in this
type of HCC, since larger liver nodules may be associated
with diminished formation of fibrotic septa and therefore
attenuation of HSC activation [51]. However, a recent study
by Yoshimoto et al. associates prolonged activation of HSC
and HCC development in obese mice without preceding
cirrhosis [53]. They found that obesity alters gut microbiota
and their metabolic product entered the liver through en-
terohepatic circulation, thus promoting hepatocarcinogen-
esis through sustained secretion of inflammatory mediators
by HSCs. It should be noted that, in this model, chronic
inflammation mainly contributes to hepatocarcinogenesis.
This study shows the crucial role of HSCs as a bridge con-
necting intestinal flora and liver parenchyma in chronic
liver inflammation.Conclusions
HSCs have traditionally been studied in the context of
liver fibrosis. However, as reviewed here, recent studies
show that they actively participate in liver inflammation
by sensing external signals, producing inflammatory cyto-
kines, and navigating T lymphocytes into the parenchyma
(Fig. 1). In some context, HSCs can elicit anti-inflammatory
actions as seen in DP1 stimulation in ConA-induced
hepatitis and expansion of immunosuppressive cells in
I/R liver injury and HCC. Further studies are required
to elucidate the unexplored roles of HSCs in the devel-
opment of hepatitis and clarify the factors that regulate
different phenotypes of HSCs. As pericyte equivalents,
further understanding of the physiology and inflamma-
tory responses of HSCs will provide deeper insights
into the actions of pericytes also in other organs and
provide novel therapeutic targets in the treatment of
inflammatory diseases of many organs including liver.Abbreviations
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